Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.

@article{Cataland2008EffectOP,
  title={Effect of prophylactic cyclosporine therapy on ADAMTS13 biomarkers in patients with idiopathic thrombotic thrombocytopenic purpura.},
  author={Spero R. Cataland and Ming Jin and Shili Lin and Eric H. Kraut and James N George and Haifeng M. Wu},
  journal={American journal of hematology},
  year={2008},
  volume={83 12},
  pages={
          911-5
        }
}
Several reports have been published regarding the use of cyclosporine (CSA) in the treatment of idiopathic thrombotic thrombocytopenic purpura (TTP). We hypothesized that prophylactic CSA therapy may prevent recurrences in patients with a history of multiple relapses of TTP. Nineteen patients with idiopathic TTP were enrolled on prospective studies at Ohio State University between September 2003 and May 2007. Patients achieving remission remained on CSA therapy for 6 months, allowing us to… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-7 OF 7 CITATIONS

Microangiopathic disorders in pregnancy.

  • Hematology/oncology clinics of North America
  • 2011

Successful treatment with cyclosporine of thrombotic thrombocytopenic purpura refractory to corticosteroids and plasma exchange.

  • Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy
  • 2011
VIEW 1 EXCERPT